267 related articles for article (PubMed ID: 21824083)
1. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
3. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
4. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
5. Conformational exchange in the potassium channel blocker ShK.
Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
[TBL] [Abstract][Full Text] [Related]
6. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
7. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
8. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
9. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
Pennington MW; Lanigan MD; Kalman K; Mahnir VM; Rauer H; McVaugh CT; Behm D; Donaldson D; Chandy KG; Kem WR; Norton RS
Biochemistry; 1999 Nov; 38(44):14549-58. PubMed ID: 10545177
[TBL] [Abstract][Full Text] [Related]
10. Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations.
Rashid MH; Kuyucak S
J Phys Chem B; 2012 Apr; 116(16):4812-22. PubMed ID: 22480371
[TBL] [Abstract][Full Text] [Related]
11. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
12. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
[TBL] [Abstract][Full Text] [Related]
13. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
14. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.
Chi V; Pennington MW; Norton RS; Tarcha EJ; Londono LM; Sims-Fahey B; Upadhyay SK; Lakey JT; Iadonato S; Wulff H; Beeton C; Chandy KG
Toxicon; 2012 Mar; 59(4):529-46. PubMed ID: 21867724
[TBL] [Abstract][Full Text] [Related]
15. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
[TBL] [Abstract][Full Text] [Related]
16. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins.
Prentis PJ; Pavasovic A; Norton RS
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316700
[TBL] [Abstract][Full Text] [Related]
17. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
Pennington MW; Harunur Rashid M; Tajhya RB; Beeton C; Kuyucak S; Norton RS
FEBS Lett; 2012 Nov; 586(22):3996-4001. PubMed ID: 23063513
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
19. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
Rauer H; Pennington M; Cahalan M; Chandy KG
J Biol Chem; 1999 Jul; 274(31):21885-92. PubMed ID: 10419508
[TBL] [Abstract][Full Text] [Related]
20. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
